Asana BioSciences Relocates Operations To Lawrenceville, New Jersey
08/24/2016
“This move was necessary to further our vision of building an oncology-focused biopharmaceutical company,” said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences. “As we continue to expand and grow, our new Princeton area location makes it ideal for us to attract key scientific and medical talent within the Central New Jersey and Philadelphia life sciences corridor.”
According to company officials, Asana continues to advance its portfolio of differentiated targeted therapies to help address major unmet medical needs, including a novel CYP17 inhibitor for prostate cancer and a dual Syk/JAK inhibitor for non-Hodgkin’s lymphoma that are in phase I/II clinical trials.
Asana BioSciences, an independent member of The Amneal Alliance of companies, is a research and development company, specializing in the discovery and development of novel drug candidates, including an antibody-drug conjugate. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Over the past year, it has been adding key talent to its team, including the appointment of a chief medical officer and expansion of its scientific advisory board.
Project Announcements
Church & Dwight Expands Old Fort, Ohio, Prodcution Operations
11/05/2025
EPC-Columbia Plans Fremont, Ohio, Manufacturing Operations
11/05/2025
Aclara Resources Plans Calcasieu Parish, Louisiana, Heavy Rare Earth Separation Operations
11/04/2025
KCG Engineering Group Plans Chesapeake, Virginia, Operations
11/04/2025
Morin Establishes Little Rock, Arkansas, Operations
11/03/2025
Provalus Plans West Plains, Missouri, Operations
11/01/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025